Back to discover
Drug

Mifepristone

In clinical development
ClassGlucocorticoid receptor antagonistEmerging researchLate-stage developmentSteady momentum
Also known as Korlym, Mifeprex, Mifepriston, Mifepristona+2 more

Korlym, Mifeprex, Mifepriston, Mifepristona, Mifépristone, Mifepristonum.

RxNorm6964ChEMBLCHEMBL1276308ATCG03XB01ATCG03XB51UNII320T6RNW1F
5
Research papers
9
Active clinical trials
2
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challenge

Regulatory2026-07-21Regulatory news · Fierce Biotech

Prospective Phase III Multi-center Open-label Study of the Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

Clinical trial2026-06-08Results expected Q2 2027 · ClinicalTrials.gov

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

Clinical trial2026-04-07Results posted · ClinicalTrials.gov

A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER

Clinical trial2026-02-25Results expected Q4 2027 · ClinicalTrials.gov

Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Clinical trial2025-09-30Terminated · ClinicalTrials.gov

Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness (GWI)-Associated Multi-symptom Disease Homeostasis Reset

Clinical trial2025-09-30Completed · ClinicalTrials.gov

Mifepristone Outpatient Labour Induction

Clinical trial2025-09-10Results expected Q4 2026 · ClinicalTrials.gov

Mifepristone Versus Misoprostol for Cervical Preparation Prior to Procedural Abortion at 12 to 16 Weeks' Gestation in an Academic Medical Center: a Randomized Controlled Pilot Trial

Clinical trial2025-08-13Results expected Q4 2026 · ClinicalTrials.gov

Effects of a True Prophylactic Treatment on Hippocampal and Amygdala Synaptic Plasticity and Gene Expression in a Rodent Chronic Stress Model of Social Defeat.

Research2023-07-07International journal of molecular sciences

Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.

Research2014-09-16Psychiatry research

Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

Research2014-03-14International journal of geriatric psychiatry

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

Research2012-03-30The Journal of clinical endocrinology and metabolism

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Mifepristone
Aliases & brands
KorlymMifeprexMifepristonMifepristonaMifépristoneMifepristonum
RxNorm CUI
6964
ChEMBL ID
CHEMBL1276308
ATC codes
G03XB01G03XB51
UNII
320T6RNW1F
Primary mechanism
Glucocorticoid receptor antagonist

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glucocorticoid receptor
NR3C1 · P04150
ANTAGONISTGlucocorticoid receptor antagonist
Progesterone receptor
PGR · P06401
ANTAGONISTProgesterone receptor antagonist

Clinical trials

124 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
124
registered trials across all phases
LATEST COMPLETION 2025
9
Active studies
7
Recruiting
75
Late-stage (III+)
73
Completed
42
Discontinued
PHASE DISTRIBUTIONn = 124
Early Phase 14Phase 19Phase 1 / 27Phase 229Phase 2 / 37Phase 323Phase 427Phase N / A18

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy: a Randomized, Non-inferiority Trial

RecruitingPH IVKK Women's and Children's Hospitaln=1442025

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

CompletedPH IVWashington University School of Medicinen=302025

Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)

CompletedPH IVKey trialCorcept Therapeuticsn=1,1132024

Comparison of Efficacy and Safety of Sequential Use of Mifepristone and Misoprostol vs Misoprostol Alone in Women With Early Pregnancy Loss: Randomized Controlled Trial

Unknown statusPH IVClinical Hospital Merkurn=2202023

Feasibility and Acceptability of Dispensing Mifepristone Via Mail Order Pharmacy

CompletedPH IVDaniel Grossman, MDn=5362023

Recent completions

Trials that read out recently, adding to the completed evidence base.

Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness (GWI)-Associated Multi-symptom Disease Homeostasis Reset

CompletedPH INova Southeastern Universityn=202025

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

CompletedPH IVWashington University School of Medicinen=302025

Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)

CompletedPH IVKey trialCorcept Therapeuticsn=1,1132024

RESET-medication: Glucocorticoid Receptor (GR) Blockade As Diseasemodifying Treatment for Depression with Childhood Trauma

CompletedPH IIAmsterdam UMC, location VUmcn=1582024

COMPARATIVE STUDY OF EFFECTS BETWEEN LETROZOLE PLUS MISOPROSTOL AND MIFEPRISTONE PLUS MISOPROSTOL IN TERMINATING NON-VIABLE FIRST TRIMESTER PREGNANCIES

CompletedPH IIICalcutta National Medical College and Hospitaln=1202024

Glucocorticoid Antagonists in Heavy Drinkers: Effects on fMRI Connectivity, Withdrawal and Drinking

CompletedPH I/IIJohns Hopkins Universityn=652024

Research activity

5 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20102023
Most influential

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

The Journal of clinical endocrinology and metabolism · 2012 · 300 cites

Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.

Psychiatry research · 2015 · 131 cites

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.

Gynecologic oncology · 2010 · 26 cites

Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

International journal of geriatric psychiatry · 2014 · 14 cites

Effects of a True Prophylactic Treatment on Hippocampal and Amygdala Synaptic Plasticity and Gene Expression in a Rodent Chronic Stress Model of Social Defeat.

International journal of molecular sciences · 2023 · 13 cites
Recent papers

Effects of a True Prophylactic Treatment on Hippocampal and Amygdala Synaptic Plasticity and Gene Expression in a Rodent Chronic Stress Model of Social Defeat.

International journal of molecular sciences · 2023 · 13 cites

Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies.

Psychiatry research · 2015 · 131 cites

Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

International journal of geriatric psychiatry · 2014 · 14 cites

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

The Journal of clinical endocrinology and metabolism · 2012 · 300 cites

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.

Gynecologic oncology · 2010 · 26 cites
Major research themes2
Mifepristone1Rodentia1
Journals, researchers & institutions
Top journals
  • Gynecologic oncology1
  • International journal of geriatric psychiatry1
  • International journal of molecular sciences1
  • Psychiatry research1
  • The Journal of clinical endocrinology and metabolism1
Leading researchers
  • Anger J1
  • Aponik L1
  • Biller BM1
  • Blumberger D1
  • Boyce Z1
  • Brady WE1
  • Brantley A1
  • Crofts T1
Leading institutions
free-text, unnormalised
  • Boston University School of Medicine1
  • Brigham Young University1
  • Columbia University College of Physicians and Surgeons1
  • Cooper University Hospital1
  • Massachusetts General Hospital and Harvard Medical School1
  • Neuroscience Center1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Propranolol

Frequently co-studied with Mifepristone in the research literature.

2 shared papers
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials